Triamcinolone acetonide sustained-release - Flexion Therapeutics

Drug Profile

Triamcinolone acetonide sustained-release - Flexion Therapeutics

Alternative Names: FX-006; Zilretta

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Flexion Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glucocorticoid receptor agonists; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Musculoskeletal pain
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Musculoskeletal pain
  • Phase II Osteoarthritis

Most Recent Events

  • 12 Dec 2016 Preregistration for Musculoskeletal pain (associated with knee osteoarthritis) in USA (Intra-articular)
  • 01 Nov 2016 Top-line efficacy data from a phase II trial in Osteoarthritis released by Flexion Therapeutics
  • 01 Nov 2016 Flexion Therapeutics completes a phase II trial in Osteoarthritis (in patients with Type-2 diabetes mellitus) in USA (NCT02762370)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top